Difference between revisions of "Team:NJU-China/Description"

(Prototype team page)
 
 
(11 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
{{IISER_Pune}}
+
<!-- saved from url=(0029)http://thefounderspledge.org/ -->
−
<html>
+
<html><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
 +
<meta charset="utf-8">
 +
<!-- Always force latest IE rendering engine or request Chrome Frame -->
 +
<meta content="IE=edge,chrome=1" http-equiv="X-UA-Compatible">
 +
<meta content="width=device-width, initial-scale=1.0, maximum-scale=1.0" name="viewport">
 +
<!-- Use title if it's in the page YAML frontmatter -->
 +
<title>humanpractice</title>
  
−
<h2> Project Description </h2>
 
  
−
<p>Tell us about your project, describe what moves you and why this is something important for your team.</p>
+
<meta content="#ffffff" name="msapplication-TileColor">
−
<br />
+
<meta content="/images/favicon/ms-icon-144x144-46dbe12c.png" name="msapplication-TileImage">
 +
<meta content="#ffffff" name="theme-color">
 +
<link href="https://2015.igem.org/Template:NJU-China/CSS1?action=raw&ctype=text/css" rel="stylesheet" type="text/css">
 +
<script async="" src="https://2015.igem.org/Template:NJU-China/JS?
 +
action=raw&ctype=text/javascript"></script><script src="https://2015.igem.org/Template:NJU-China/JS2?
 +
action=raw&ctype=text/javascript" type="text/javascript"></script>
 +
<link href="https://2015.igem.org/Template:NJU-China/CSS2?action=raw&ctype=text/css" rel="stylesheet" type="text/css">
 +
<link href="https://2015.igem.org/Template:NJU-China/CSS3?action=raw&ctype=text/css" rel="stylesheet" type="text/css">
 +
<link href="https://2015.igem.org/Template:NJU-China/CSS4?action=raw&ctype=text/css" rel="stylesheet" type="text/css">
 +
<style type="text/css">
  
−
<h5>What should this page contain?</h5>
+
body {
−
<ul>
+
background-image: url(https://static.igem.org/mediawiki/2014/b/bd/HUST_Background_3.jpg);
−
<li> A clear and concise description of your project.</li>
+
/*background-color: #F99; */
−
<li>A detailed explanation of why your team chose to work on this particular project.</li>
+
}
−
<li>References and sources to document your research.</li>
+
−
<li>Use illustrations and other visual resources to explain your project.</li>
+
−
</ul>
+
  
 +
#footer-box {
 +
    background-color: transparent;
 +
}
  
−
<br />
+
#sponsor-box {
−
<h4>Advice on writing your Project Description</h4>
+
    background-color: transparent;
 +
}
  
−
<p>
+
.shadow3 {
−
We encourage you to put up a lot of information and content on your wiki, but we also encourage you to include summaries as much as possible. If you think of the sections in your project description as the sections in a publication, you should try to be consist, accurate and unambiguous in your achievements.
+
background-color: transparent;
−
</p>
+
}
  
−
<p>
+
#content {
−
Judges like to read your wiki and know exactly what you have achieved. This is how you should think about these sections; from the point of view of the judge evaluating you at the end of the year.
+
    background: transparent;  
−
</p>
+
}
  
 +
table {
 +
    background: transparent;
 +
}
  
−
<br />
+
#catlinks {
−
<h4>References</h4>
+
    visibility: hidden;
−
<p>iGEM teams are encouraged to record references you use during the course of your research. They should be posted somewhere on your wiki so that judges and other visitors can see how you though about your project and what works inspired you.</p>
+
}
  
 +
.mediawiki.ltr.ns-0.ns-subject.page-Team_HUST-China
 +
#globalWrapper #top-section #p-logo a img {
 +
    visibility:hidden;
 +
}
  
 +
#p-logo {
 +
    background:url(https://static.igem.org/mediawiki/2014/5/52/Wiki_Logo_Transparent.png);
 +
 
 +
background-repeat: no-repeat;
 +
}
  
−
<h4>Inspiration</h4>
+
.firstHeading {
−
<p>See how other teams have described and presented their projects: </p>
+
visibility:hidden;
 +
}
 +
</style>
  
 +
<style>
 +
#contentSub, #footer-box, #catlinks, #search-controls, #p-logo, .printfooter, .firstHeading, .visualClear{display: none;}
 +
 +
#globalWrapper, #content { /*-- changes default wiki settings --*/
 +
 
 +
width: 100%;
 +
    height: 100%;
 +
    border: 0px;
 +
    background-color: transparent;
 +
    margin: 0px;
 +
    padding: 0px;
 +
}
 +
 +
 +
html, body, .wrapper { /*-- changes default wiki settings --*/
 +
   
 +
width: 100%;
 +
    height: 100%;
 +
    background-color: transparent; 
 +
}
 +
#top-section {
 +
    background-color:4848;
 +
    border: 0 none;
 +
    width: 100%;
 +
    height: 24px;
 +
    z-index: 100;
 +
    top: 0;
 +
    position: fixed;
 +
}
 +
 +
 +
#menubar {
 +
    top: 2px;
 +
    font-family: Helvetica, Arial, Sans-serif;
 +
    font-size: 14px;
 +
}
 +
 +
.new {
 +
    color:white;
 +
}
 +
 +
a, a:visited {
 +
    color: #ADADAD;
 +
    text-decoration: none;
 +
}
 +
 +
a:hover {
 +
    color: white;
 +
    text-decoration: underline;
 +
}
 +
 +
#apDiv_Logo_iGEM {
 +
position:absolute;
 +
right:200px;
 +
top:80px;
 +
width: 100px;
 +
height: 100px;
 +
z-index: 5;
 +
}
 +
</style>
 +
 +
 +
<style type="text/css">
 +
    *{ margin:0; padding:0;    list-style:none;}
 +
    #nav a { text-decoration:underline;color:#06c; font-size:14px; line-height:24px;text-decoration: none;}
 +
    #nav ul{ margin-bottom:5px;}
 +
    #nav strong{ color:#696;}
 +
    #nav.dyn li ul{ display:none;}
 +
    #nav.dyn li ul.show{ display:block;}
 +
    #nav.dyn li{ padding-left:15px;line-height:250%}
 +
</style>
 +
 +
 +
</head>
 +
 +
<body class="index" data-view="index" style="">
 +
<div class="content">
 +
<nav>
 
<ul>
 
<ul>
−
<li><a href="https://2014.igem.org/Team:Imperial/Project"> Imperial</a></li>
+
<li><a class="button" href="#detail" style="font-weight:bold;font-family:Microsoft YaHei">content</a></li>
−
<li><a href="https://2014.igem.org/Team:UC_Davis/Project_Overview"> UC Davis</a></li>
+
−
<li><a href="https://2014.igem.org/Team:SYSU-Software/Overview">SYSU Software</a></li>
+
 
</ul>
 
</ul>
 +
</nav>
 +
<div id='menu-toggle'>
 +
<div class='menu-icon'><img src="menu-fe5f9c80.svg" /></div>
 +
</div>
  
 +
 +
<div id="header" style="background-image:url(https://static.igem.org/mediawiki/2015/f/ff/NJU-China-project.jpg);background-size:cover">
 +
<div class="header-content">
 +
<div class="container">
 +
<div class="row">
 +
<div class="col-md-12">
 +
<div class="scroll-link-wrapper" style="visibility: visible;margin-top:500px ">
 +
<a class="scroll-link" href="#detail"><img src="https://static.igem.org/mediawiki/2015/1/16/NJU-China-file-arrow_down.png">
 +
</a></div>
 
</div>
 
</div>
−
</html>
+
</div>
 +
</div>
 +
</div>
 +
</div>
 +
 
 +
 
 +
 
 +
 
 +
 
 +
<div id="detail">
 +
<TABLE borderColor=#00ff99 height="100%" width="100%" border=0 style="table-layout:fixed">
 +
    <TR height="100%">
 +
<TD width="27%" bgColor=#E6E8FA style="vertical-align:top">
 +
</br>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/Team:NJU-China" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Home</a></li>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/NJU-China-background.html" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Background</a></li>
 +
<div style="line-height:250%;margin-left:10%" id="main1" onClick="document.all.child0.style.display=(document.all.child0.style.display =='none')?'':'none'" ><a href="#" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Project</a></div>
 +
<div id="child0" style="display:none">
 +
<ul>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/Team:NJU-China/Design" style="font-weight:bold;font-family:幼圆;color:black">design</a></li>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/NJU-China-project/result.html" style="font-weight:bold;font-family:幼圆;color:black">results</a></li>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/NJU-China-project/conclusion.html" style="font-weight:bold;font-family:幼圆;color:black">conclusion</a></li>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/NJU-China-project/future work.html" style="font-weight:bold;font-family:幼圆;color:black">future work</a></li>
 +
</ul>
 +
</div>
 +
<div style="line-height:250%;margin-left:10%" id="main1" onClick="document.all.child1.style.display=(document.all.child1.style.display =='none')?'':'none'" ><a href="#" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Model</a></div>
 +
<div id="child1" style="display:none">
 +
<ul>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/NJU-China-model.html" style="font-weight:bold;font-family:幼圆;color:black">Delivery model</a></li>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/Team:NJU-China/RNAi" style="font-weight:bold;font-family:幼圆;color:black">RNAi model</a></li>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/Team:NJU-China/signaling" style="font-weight:bold;font-family:幼圆;color:black">Signaling</a></li>
 +
</ul>
 +
</div>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/Team:NJU-China/Practices" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Human Practice</a></li>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/NJU-China-parts.html" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Parts</a></li>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/NJU-China-team.html" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Team</a></li>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/NJU-China-attribution.html" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Attribution</a></li>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/Team:NJU-China/Collaborations" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Colaborations</a></li>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/NJU-China-safty.html" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Safety</a></li>
 +
<div style="line-height:250%;margin-left:10%" id="main2" onClick="document.all.child2.style.display=(document.all.child2.style.display =='none')?'':'none'" > <a href="#" style="font-weight:bold;font-family:幼圆;font-size:25px;color:black">Notebook </div>
 +
<div id="child2" style="display:none">
 +
<ul>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/NJU-China-notebook.html#methods" style="font-weight:bold;font-family:幼圆;font-size:20px;color:black">Methods</a></li>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/NJU-China-notebook.html#protocal" style="font-weight:bold;font-family:幼圆;font-size:20px;color:black">Protocal</a></li>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/NJU-China-notebook.html#notebook" style="font-weight:bold;font-family:幼圆;font-size:20px;color:black">Notebook</a></li>
 +
</ul>
 +
</div>
 +
<li style="line-height:250%;margin-left:10%"><a href="https://2015.igem.org/NJU-China-acknowledgement.html#notebook" style="font-weight:bold;font-family:幼圆;font-size:20px;color:black">Acknowledgement</a></li>
 +
 
 +
 
 +
</TD>
 +
    <TD width="73%" bgColor=#FFFFFF style="vertical-align:top;padding-left:80px;padding-right:80px;padding-top:50px;padding-bottom:50px;word-wrap:break-word;">
 +
<img src="https://static.igem.org/mediawiki/2015/9/90/NJU-China-Design-overview.gif" style="width:400px;height:300px;float:left;border:0">
 +
Illegal drugs are highly addictive and pose serious health risks. Addiction to drugs is a painful battle for the addict as well as for those individuals around him or her. Opioids and opiates top the list of problem drugs and cause the greatest burden of disease and drug-related deaths worldwide. The goal of this project is to develop a strategy to treat opioid addiction and to reduce relapse. Because opioids act primarily as Mu-opioid receptor (MOR) agonist to activate the reward pathway in the brain, leading to the euphoric effect of opioid drugs and ultimately the opioid-dependent state, blockage of the expression and function of MOR would theoretically have therapeutic value in the treatment of opioid dependence. Thus, this project selects MOR as a therapeutic target for the treatment of opioid addiction and for the prevention of a relapse to opioid use.
 +
</br></br>
 +
siRNAs are emerging as promising therapeutic drugs against a wide array of diseases. The key obstacle for successful clinical application of siRNA is to develop a safe and effective delivery system directed at the target tissues only. Current techniques for small RNA transfer use viruses or synthetic agents as delivery vehicles. The replacement of these delivery vehicles with a low toxicity and high target-specific approach is essential for making siRNA therapy feasible.  Because exosomes have the intrinsic ability to traverse biological barriers and to naturally transport functional small RNAs between cells, exosomes potentially represent a novel and exciting delivery vehicle for the field of siRNA therapy. As therapeutic delivery agents, exosomes will potentially be better tolerated by the immune system because they are natural nanocarriers derived from endogenous cells. Furthermore, exosomes derived from cells engineered to express siRNAs and surface proteins may be capable of delivering these small RNAs to the target cells. Thus, exosome-based delivery of siRNAs may provide an untapped source of effective delivery strategy to overcome impediments such as inefficiency, unspecificity and immunogenic reactions.
 +
</br></br>
 +
In iGEM 2013, our team, NJU-China, constructed a part (BBa_K1180002) expressing the neuron-targeting peptide RVG. We got some preliminary data to show that RVG-exosomes can somewhat target the brain. In the project of this year, we study intensively its function both in vitro and in vivo and expand its application by integrating it with another part that expresses MOR siRNA. We propose a strategy of using RVG exosomes to encapsulate MOR siRNA and specifically deliver them to the brain. We also entered the experiment data in the part's page on the Registry. As a consequence, RVG exosome-delivered MOR siRNA can reversibly block or attenuate the effects of opioids, thereby functions as therapeutics for the prevention of relapse to opioid dependence following detoxification.
 +
 
 +
</TD>
 +
    </TR>
 +
</TABLE>
 +
</div>
 +
 
 +
 
 +
</div>
 +
 
 +
 
 +
</body></html>

Latest revision as of 18:57, 18 September 2015

humanpractice


  • Home
  • Background
  • Human Practice
  • Parts
  • Team
  • Attribution
  • Colaborations
  • Safety
  • Acknowledgement
    		•  Illegal drugs are highly addictive and pose serious health risks. Addiction to drugs is a painful battle for the addict as well as for those individuals around him or her. Opioids and opiates top the list of problem drugs and cause the greatest burden of disease and drug-related deaths worldwide. The goal of this project is to develop a strategy to treat opioid addiction and to reduce relapse. Because opioids act primarily as Mu-opioid receptor (MOR) agonist to activate the reward pathway in the brain, leading to the euphoric effect of opioid drugs and ultimately the opioid-dependent state, blockage of the expression and function of MOR would theoretically have therapeutic value in the treatment of opioid dependence. Thus, this project selects MOR as a therapeutic target for the treatment of opioid addiction and for the prevention of a relapse to opioid use.

    siRNAs are emerging as promising therapeutic drugs against a wide array of diseases. The key obstacle for successful clinical application of siRNA is to develop a safe and effective delivery system directed at the target tissues only. Current techniques for small RNA transfer use viruses or synthetic agents as delivery vehicles. The replacement of these delivery vehicles with a low toxicity and high target-specific approach is essential for making siRNA therapy feasible. Because exosomes have the intrinsic ability to traverse biological barriers and to naturally transport functional small RNAs between cells, exosomes potentially represent a novel and exciting delivery vehicle for the field of siRNA therapy. As therapeutic delivery agents, exosomes will potentially be better tolerated by the immune system because they are natural nanocarriers derived from endogenous cells. Furthermore, exosomes derived from cells engineered to express siRNAs and surface proteins may be capable of delivering these small RNAs to the target cells. Thus, exosome-based delivery of siRNAs may provide an untapped source of effective delivery strategy to overcome impediments such as inefficiency, unspecificity and immunogenic reactions.

    In iGEM 2013, our team, NJU-China, constructed a part (BBa_K1180002) expressing the neuron-targeting peptide RVG. We got some preliminary data to show that RVG-exosomes can somewhat target the brain. In the project of this year, we study intensively its function both in vitro and in vivo and expand its application by integrating it with another part that expresses MOR siRNA. We propose a strategy of using RVG exosomes to encapsulate MOR siRNA and specifically deliver them to the brain. We also entered the experiment data in the part's page on the Registry. As a consequence, RVG exosome-delivered MOR siRNA can reversibly block or attenuate the effects of opioids, thereby functions as therapeutics for the prevention of relapse to opioid dependence following detoxification.